Professional
Added to YB: 2024-10-04
Pitch date: 2024-10-03
GH [bullish]
Guardant Health, Inc.
+95.04%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
Market Cap
$5.9B
Pitch Price
$21.99
Price Target
47.00 (+16%)
Dividend
N/A
Sector
Health Care Providers and Services
Category
growth
Show full summary:
Guardant Health, Inc.: Strong Volume Growth; Guidance Revised Upward
GH: Liquid biopsy leader in genomic profiling, MRD testing, CRC screening. Guardant360 FDA-approved for CGP. Reveal MRD test launched 2021, Shield CRC screening LDT 2022. Targeting FDA approval 2024, USPSTF inclusion 2026. No moat, high uncertainty. FV $47. Cash flow positive by 2028. $4B revenue by 2032.
Read full article (8 min)